{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["52"],"submitter":["Kalfon P"],"pubmed_abstract":["<h4>Background</h4>Severe hypoxemia in patients with COVID-19 pneumonia might result from hypoxic pulmonary vasoconstriction, contributing to ventilation/perfusion (V/Q) mismatch. Because almitrine improves V/Q, it might reduce the risk for mechanical ventilation (MV) in such patients. Our primary objective was to determine the effect of almitrine on the need for MV at day 7.<h4>Methods</h4>In a randomised double-blind placebo-controlled trial involving 15 ICUs, patients hospitalized for COVID-19 pneumonia and experiencing acute hypoxemic respiratory failure were randomly assigned to receive 5 days of intravenous low-dose (2 µg.kg<sup>-1</sup>.min<sup>-1</sup>) almitrine or placebo. The primary outcome was endotracheal intubation for MV or death within 7 days after randomisation. Secondary"],"journal":["EClinicalMedicine"],"pagination":["101663"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9489996"],"repository":["biostudies-literature"],"pubmed_title":["Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial."],"pmcid":["PMC9489996"],"pubmed_authors":["Rousseau A","Chousterman B","Depret F","Simon T","Kalfon P","Tibi A","Weiss E","Riou B","Audibert J","Constantin JM","Remerand F","Payen JF","Freund Y","Cachanado M"],"additional_accession":[]},"is_claimable":false,"name":"Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial.","description":"<h4>Background</h4>Severe hypoxemia in patients with COVID-19 pneumonia might result from hypoxic pulmonary vasoconstriction, contributing to ventilation/perfusion (V/Q) mismatch. Because almitrine improves V/Q, it might reduce the risk for mechanical ventilation (MV) in such patients. Our primary objective was to determine the effect of almitrine on the need for MV at day 7.<h4>Methods</h4>In a randomised double-blind placebo-controlled trial involving 15 ICUs, patients hospitalized for COVID-19 pneumonia and experiencing acute hypoxemic respiratory failure were randomly assigned to receive 5 days of intravenous low-dose (2 µg.kg<sup>-1</sup>.min<sup>-1</sup>) almitrine or placebo. The primary outcome was endotracheal intubation for MV or death within 7 days after randomisation. Secondary","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-27T18:55:29.101Z","creation":"2025-04-19T09:53:52.407Z"},"accession":"S-EPMC9489996","cross_references":{"pubmed":["36157895"],"doi":["10.1016/j.eclinm.2022.101663"]}}